tbuckley/cabot-search huggingface dataset:
Isavuconazole in Hematological Patients: Results of a Real-Life Multicentre Observational Seifem Study
Authors: Chiara Cattaneo, Alessandro Busca, Doriana Gramegna, Francesca Farina, Anna Candoni, Monica Piedimonte, Nicola Fracchiolla, Chiara Pagani, Maria Ilaria Del Principe, Maria Chiara Tisi, Massimo Offidani, Rosa Fanci, Stelvio Ballanti, Angelica Spolzino, Marianna Criscuolo, Francesco Marchesi, Gianpaolo Nadali, Mario Delia, Marco Picardi, Margherita Sciumé, Valentina Mancini, Attilio Olivieri, Mario Tumbarello, Giuseppe Rossi, Livio Pagano
Journal: HemaSphere (2019)

Abstract Invasive fungal diseases (IFDs) remain a major clinical issue in patients with hematological malignancies (HMs). To confirm the efficacy and safety of the new azole isavuconazole (ISV) in a clinical care setting, we planned a multicenter retrospective study; we collected data on all possible/probable/proven IFDs in patients with HMs treated with ISV in 17 centers. Between July 2016 and November 2018, 128 patients were enrolled, and 122 were fully evaluable. ISV was employed as the 1 st line therapy in 43 (35%) patients and as a subsequent therapy in 79 (65%) patients. The response rate was 82/122 patients (67.2%); it was similar when using ISV as a 1st or 2nd line treatment (60.5% vs 70.9%, respectively; p = 0.24). In multivariate analysis, both female sex (OR: 2.992; CI: 1.22–7.34) and induction phase of treatment (OR: 3.953; CI: 1.085–14.403) were predictive of a favorable response. At a median follow-up of 5 months, 43 (35.2%) patients were dead; the 1-year overall survival (OS) was 49.9%. In multivariate analysis, the response to ISV (OR: 0.103; CI: 0.041–0.262) and IFD refractoriness to previous antifungals (OR: 3.413; CI: 1.318–8.838) were statistically significant for OS. Adverse events (AEs) were reported in 15/122 patients (12.3%); grade 3–4 AEs were reported in 5 (4%) and led to ISV discontinuation. Our study confirms the safety and tolerability of ISV, also in diseases other than acute leukemia. Phase of hematological disease, gender and refractoriness to previous antifungals are the main predictive factors for the aforementioned response and outcome.
Surface Antigens Identified by Antibody Microarray That Correlate with IgVH Mutational Status and ZAP70 Expression in CLL.
Authors: William G. Wierda, S. Mulligan, B. Shelvin, L. Belov, L. Rassenti, T. Kipps, S. Lerner, M. Thomas, H. Kantarjian, M. Keating
Journal: Blood (2005)
Echocardiographic assessment of end-diastolic wall thickness can be used as a marker of reperfusion in transmural and partial-thickness infarcts
Authors: Lieven Herbots, E Eroglu, Jan D'hooge, Piet Claus, Oambrauskaite, Javier Ganame, P Mehvald, Bart Bijnens, Stefan Janssens, Frank Rademakers, GR Sutherland
Journal: Circulation (2004)
Second Report of Clinical Significance of sFas for DLBCL Treated with CHOP and New Analysis of sFas for DLBCL Treated with R-CHOP.
Authors: Hisashi Tsurumi, Takeshi Hara, Jun-ichi Kitagawa, Naoe Goto, Nobuhiro Kanemura, Senji Kasahara, Toshiki Yamada, Hisataka Moriwaki
Journal: Blood (2007)
Hematopoietic Stem Cells Fail to Trans-Differentiate into Smooth Muscle-Lineage Cells In Vivo.
Authors: Takafumi Yokota, Sanai Sato, Yutaka Kawakami, Yoshinori Nagai, Jian-xing Ma, Jen-Yue Tsai, Kenji Oritani, Yoshiaki Tomiyama, Itaru Matsumura, Paul W. Kincade, Yuzuru Kanakura
Journal: Blood (2005)
Association Between Adolescent Blunt Use and the Uptake of Cigars
Authors: Janet Audrain-McGovern, Daniel Rodriguez, Emily Alexander, Stephen Pianin, Kymberle Landrum Sterling
Journal: JAMA Network Open (2019)

<h3>Importance</h3> Almost two-thirds of adolescents who smoke blunts also report using cigars. Although adolescent co-use of blunts and cigars is prevalent, whether adolescent blunt use is associated with progression to current cigar use (past 30-day use) and increased frequency of use is unknown. <h3>Objective</h3> To determine whether adolescent use of blunts is associated with progression to cigar use (past 30-day use) and increased number of days used (in the past 30 days) across the subsequent 24 months compared with adolescents who have never used blunts. <h3>Design, Setting, and Participants</h3> In this prospective cohort study of adolescents from 4 public high schools outside of Philadelphia, Pennsylvania, in-classroom surveys were administered at baseline (fall 2016, beginning of 9th grade) and at 6-month intervals for the following 24 months (fall 2018, beginning of 11th grade). Data analyses were conducted in September and October 2019. <h3>Exposures</h3> Self-report of lifetime (ever) blunt use at baseline (age 14 years). <h3>Main Outcomes and Measures</h3> Progression to current cigar use (use in the past 30 days) and escalation in the frequency of use (number of days used in the past 30 days) across the subsequent 24 months. <h3>Results</h3> Of 1825 participants, 907 (49.7%) were female, 1330 (72.9%) were white, and 376 (20.6%) were Hispanic; the mean (SD) age at baseline was 14.38 (0.55) years. In all, 257 participants (14.0%) reported ever blunt use. Mixed-effects models revealed that ever blunt use at baseline vs never blunt use was associated with progression to current cigar use (past 30 days use: odds ratio, 22.66; 95% CI, 11.34-45.27) but not escalation in the number of days used across the following 24 months (β = 0.13; 95% CI, −0.17 to 0.43). <h3>Conclusions and Relevance</h3> These findings highlight the risk that blunt use may pose for subsequent cigar use among adolescents. Policies and public health campaigns addressing marijuana as well as cigars will be important to reduce adolescent blunt use and cigar use.
Levofloxacine Prophylaxis Decreases the Incidence of BK Polyoma Virus-Induced Hemorrhagic Cystitis in Patients after Allogeneic Hematopoietic Stem Cell Trans-Plantation
Authors: Yoko Ono, Manja Lache, Florian Jacob, Dominik Schneidawind, Anita Schmitt, Detlef Michel, Thomas Mertens, Hartmut Döhner, Donald Bunjes, Michael Schmitt
Journal: Blood (2008)
Childhood Secondary ALL after ALL Treatment.
Authors: Jan Zuna, Cornelia Eckert, Hélène Cavé, Claus Meyer, Björn Schneider, Eva Fronkova, Katerina Muzikova, Denisa Mendelova, Patrick Boutard, André Schrauder, Jaroslav Sterba, Rolf Marschalek, Jan Stary, Jan Trka
Journal: Blood (2005)
A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer
Authors: Cristina P. Rodriguez, Qian (Vicky) Wu, Jenna Voutsinas, Jonathan R. Fromm, Xiuyun Jiang, Venu G. Pillarisetty, Sylvia M. Lee, Rafael Santana-Davila, Bernardo Goulart, Christina S. Baik, Laura Q.M. Chow, Keith Eaton, Renato Martins
Journal: Clinical Cancer Research (2019)

Abstract Purpose: This clinical trial combined pembrolizumab and vorinostat in recurrent/metastatic squamous cell carcinomas of the head and neck (HN), and salivary gland cancer (SGC). Patients and Methods: Patients with progressing incurable HN and SGC, Eastern Cooperative Oncology Group (ECOG) ≤1, no prior immunotherapy, RECIST1.1 measurable disease, and normal organ function were eligible. Pembrolizumab 200 mg was given intravenous every 21 days, and vorinostat 400 mg given orally 5 days on and 2 days off during each 21-day cycle. Primary endpoints were safety and objective response rates. Results: From November 2015 to August 2017, 25 patients with HN and 25 SGC were enrolled. Median age was 61 (range, 33–86) years, 39 (78%) were male, 21 (62%) were never smokers, and 27 (54%) had ECOG 0. In HN, 13 (52%) were p16+ oropharynx. Most common SGC histologies were adenoid cystic 12 (48%), acinic cell 3 (12%), and mucoepidermoid 3 (12%). Adverse events (AEs) in all patients were: 27 (54%) with grade ≥ 1 and 18 (36%) with grade ≥ 3. The most common AEs in all patients were renal insufficiency in seven, (14%), fatigue in six, (12%), and nausea in three (6%). There were three (12%) deaths on study. Responses in HN were complete response (CR) 0, partial response (PR) eight (32%), and stable disease (SD) five (20%). Efficacy in SGCs was CR 0, PR four (16%) in one lymphoepithelioma-like carcinoma, two acinic cell, one adenoid cystic, and SD 14 (56%). In the HN group, median follow-up (mFUP) was 12.6 months, median overall survival (mOS) was 12.6 months, and median progression-free survival (mPFS) was 4.5 months. In SGC, mFUP was 13.1 months, mOS was 14.0 months, and mPFS was 6.9 months. Conclusions: This combination demonstrated activity in HN, with fewer responses in SGC. Toxicities were higher than reported with pembrolizumab alone.
乳腺癌与吸烟有关吗？——可能有关系，尤其在那些很年轻就开始吸烟的人
Authors: 于舒飞, 王燕
Journal: BMJ (2011)

过去的几十年中，在许多国家吸烟习惯发生了改变，因此与烟草相有关的发病及死亡逐渐从男性转移到女性。将吸烟或接触二手烟列为乳腺癌的病因可能会有力地促进女性戒烟或避免二手烟。尽管进行烟草控制是值得提倡的，但对于乳腺癌与吸烟的相关性必须谨慎评估。
Voriconazole Is Safe and Effective as a Prophylactic Regimen of Invasive Fungal Infections for High Risk Patients after Reduced-Intensity Umbilical Cord Blood Transplantation
Authors: Shinsuke Takagi, Kazuya Ishiwata, Masanori Tsuji, Hisashi Yamamoto, Daisuke Kato, Sachiko Seo, Naofumi Matsuno, Naoyuki Uchida, Kazuhiro Masuoka, Atsushi Wake, Shigeyoshi Makino, Akiko Yoneyama, Shuichi Taniguchi
Journal: Blood (2008)
Epidemiological Study on Survival of Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) Patients with T315I Mutation. Final Analysis
Authors: Franck E Nicolini, Giovanni Martinelli, Dong-Wook Kim, Andreas Hochhaus, Michael J. Mauro, Jorge Cortes, Charles Chuah, Inge Dufva, Jane F. Apperley, Fumiharu Yagasaki, Jay Pearson, Senaka Peter, Cesar Sanz Rodriguez, Frank Giles, John M Goldman, Wei Zhou
Journal: Blood (2008)
关注慢性疾病——以病人为中心的协调的医疗机制已见成效，现在应该检验其作用
Authors: 陈波斌, 林果为
Journal: BMJ (2004)

慢性病的临床特点各不相同，但是每一种疾患都使患者及其家庭面临同样的要求：改变行为方式；解决由疾病引起的症状、致残和濒临死亡所带来的社会和情感问题；服药；需要更多的互动式治疗。反之，医生必须确保患者得到最佳的治疗，控制疾病和缓解症状，同时要使患者得到有效的医疗保健信息，支持患者加强自我健康管理，甚至还包括对死亡的认知。证据表明，我们做的还不够好，但主要过错不在我们自己，而多数在于我们的医疗保健体系。
Multimodular Analysis of Angiogenic Biomarkers in the Primary Treatment of Multiple Myeloma: Correlative Studies of the BiRD Trial.
Authors: David K. Jin, Lauren M. Young, Loic Vincent, Udi Gelbshtein, Karen Pekle, George Lam, Koji Shido, Hearn J. Cho, Roger Pearse, John P. Leonard, Selina Chen-Kiang, Morton Coleman, Shahin Rafii, Ruben Niesvizky
Journal: Blood (2005)
Multiple Sources of the Outbreak of Legionnaires’ Disease in Genesee County, Michigan, in 2014 and 2015
Authors: Anya F. Smith, Anke Huss, Samuel Dorevitch, Leo Heijnen, Vera H. Arntzen, Megan Davies, Mirna Robert-Du Ry van Beest Holle, Yuki Fujita, Antonie M. Verschoor, Bernard Raterman, Frank Oesterholt, Dick Heederik, Gertjan Medema
Journal: Environmental Health Perspectives (2019)

Background: A community-wide outbreak of Legionnaires' disease (LD) occurred in Genesee County, Michigan, in 2014 and 2015. Previous reports about the outbreak are conflicting and have associated the outbreak with a change of water source in the city of Flint and, alternatively, to a Flint hospital. Objective: The objective of this investigation was to independently identify relevant sources of Legionella pneumophila that likely resulted in the outbreak. Methods: An independent, retrospective investigation of the outbreak was conducted, making use of public health, health care, and environmental data and whole-genome multilocus sequence typing (wgMLST) of clinical and environmental isolates. Results: Strong evidence was found for a hospital-associated outbreak in both 2014 and 2015: a) 49% of cases had prior exposure to Flint hospital A, significantly higher than expected from Medicare admissions; b) hospital plumbing contained high levels of L. pneumophila; c) Legionella control measures in hospital plumbing aligned with subsidence of hospital A-associated cases; and d) wgMLST showed Legionella isolates from cases exposed to hospital A and from hospital plumbing to be highly similar. Multivariate analysis showed an increased risk of LD in 2014 for people residing in a home that received Flint water or was located in proximity to several Flint cooling towers. Discussion: This is the first LD outbreak in the United States with evidence for three sources (in 2014): a) exposure to hospital A, b) receiving Flint water at home, and c) residential proximity to cooling towers; however, for 2015, evidence points to hospital A only. Each source could be associated with only a proportion of cases. A focus on a single source may have delayed recognition and remediation of other significant sources of L. pneumophila. https://doi.org/10.1289/EHP5663
Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2–Positive Esophageal Adenocarcinoma: TRAP Study
Authors: Charlotte I. Stroes, Sandor Schokker, Aafke Creemers, Remco J. Molenaar, Maarten C.C.M. Hulshof, Stephanie O. van der Woude, Roel J. Bennink, Ron A.A. Mathôt, Kausilia K. Krishnadath, Cornelis J.A. Punt, Rob H.A. Verhoeven, Martijn G.H. van Oijen, Geert-Jan Creemers, Grard A.P. Nieuwenhuijzen, Maurice J.C. van der Sangen, Laurens V. Beerepoot, Joos Heisterkamp, Maartje Los, Marije Slingerland, Annemieke Cats, Geke A.P. Hospers, Maarten F. Bijlsma, Mark I. van Berge Henegouwen, Sybren L. Meijer, Hanneke W.M. van Laarhoven
Journal: Journal of Clinical Oncology (2019)

Approximately 15% to 43% of esophageal adenocarcinomas (EACs) are human epidermal growth factor receptor 2 (HER2) positive. Because dual-agent HER2 blockade demonstrated a survival benefit in breast cancer, we conducted a phase II feasibility study of trastuzumab and pertuzumab added to neoadjuvant chemoradiotherapy (nCRT) in patients with EAC.
Risk of Rapid Kidney Function Decline, All-Cause Mortality, and Major Cardiovascular Events in Nonalbuminuric Chronic Kidney Disease in Type 2 Diabetes
Authors: Oyunchimeg Buyadaa, Dianna J. Magliano, Agus Salim, Digsu N. Koye, Jonathan E. Shaw
Journal: Diabetes Care (2019)

OBJECTIVE We aimed to investigate the rate of progression of nonalbuminuric chronic kidney disease (CKD) to end-stage kidney disease (ESKD) or death or major cardiovascular events (MACE) compared with albuminuric and nonalbuminuric phenotypes. RESEARCH DESIGN AND METHODS We included 10,185 participants with type 2 diabetes enrolled in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study. Based on baseline albuminuria and estimated glomerular filtration rate (eGFR), participants were classified as having no kidney disease (no CKD), albuminuria only (albuminuric non-CKD), reduced eGFR only (nonalbuminuric CKD), or both albuminuria and reduced eGFR (albuminuric CKD). The rate of eGFR decline and hazard ratios (HRs) for ESKD or death or MACE were calculated. RESULTS For individuals with no CKD and those with nonalbuminuric CKD, the rates of eGFR decline were −1.31 and −0.60 mL/min/year, respectively (P &amp;lt; 0.001). In competing-risks analysis (no CKD as the reference), HRs for ESKD indicated no increased risk for nonalbuminuric CKD (0.76 [95% CI 0.34, 1.70]) and greatest risk for albuminuric CKD (4.52 [2.91, 7.01]). In adjusted Cox models, HRs for death and MACE were highest for albumuniuric CKD (2.38 [1.92, 2.90] and 2.37 [1.89, 2.97], respectively) and were higher for albuminuric non-CKD (1.82 [1.59, 2.08] and 1.88 [1.63, 2.16], respectively) than for those with nonalbuminuric CKD (1.42 [1.14, 1.78] and 1.44 [1.13, 1.84], respectively). CONCLUSIONS Those with nonalbuminuric CKD showed a slower rate of decline in eGFR than did any other group; however, these individuals still carry a greater risk for death and MACE than do those with no CKD.
The novel thyromimetic KAT-681 promotes macrophage reverse cholesterol transport in vivo and protects from atherosclerosis
Authors: Ivan Tancevski, Andreas Wehinger, Egon Demetz, Kristina Duwensee, Philipp Eller, Wilfried Schgoer, Catherine Fievet, Frans Stellaard, Mats Rudling, Josef R. Patsch, Andreas Ritsch
Journal: Circulation (2007)
GD2 Peptide Mimotope DNA Vaccines for Anti-Neuroblastoma Immunotherapy.
Authors: Stefan Fest, Kerstin Hilt, Nicole Huebener, Yan Zeng, Anne Strandsby, Silke Weixler, Gerhard Gaedicke, Angelika Riemer, Elisabeth Foerster-Waldl, Erika Jensen-Jarolim, Holger N. Lode
Journal: Blood (2004)
High-resolution 3D visualization of nanomedicine distribution in tumors
Authors: Jennifer I. Moss, Hervé Barjat, Sally-Ann Emmas, Nicole Strittmatter, Juliana Maynard, Richard J. A. Goodwin, Gert Storm, Twan Lammers, Sanyogitta Puri, Marianne B. Ashford, Simon T. Barry
Journal: Theranostics (2019)

To improve the clinical translation of anti-cancer nanomedicines, it is necessary to begin building specific insights into the broad concept of the Enhanced Permeability and Retention (EPR) effect, using detailed investigations of the accumulation, distribution and retention of nanomedicines in solid tumors. Nanomedicine accumulation in preclinical tumors has been extensively studied; however, treatment efficacy will be heavily influenced by both the quantity of drug-loaded nanomedicines reaching the tumor as well as their spatial distribution throughout the tumor. It remains a challenge to image the heterogeneity of nanomedicine distribution in 3 dimensions within solid tumors with a high degree of spatial resolution using standard imaging approaches. Methods: To achieve this, an ex vivo micro computed tomography (µCT) imaging approach was developed to visualize the intratumoral distribution of contrast agent-loaded PEGylated liposomes. Using this semi-quantitative method, whole 3-dimensional (3D) tumor liposome distribution was determined with 17 µm resolution in a phenotypically diverse panel of four preclinical xenograft and patient-derived explant (PDX) tumor models. Results: High-resolution ex vivo μCT imaging revealed striking differences in liposome distribution within tumors in four models with different vascular patterns and densities, stromal contents, and microenvironment morphologies. Following intravenous dosing, the model with the highest density of pericyte-supported vessels showed the greatest liposome accumulation, while the model with vessels present in regions of high α-smooth muscle actin (αSMA) content presented with a large proportion of the liposomes at depths beyond the tumor periphery. The two models with an unsupported vascular network demonstrated a more restricted pattern of liposome distribution. Conclusion: Taken together, vessel distribution and support (the latter indicative of functionality) appear to be key factors determining the accumulation and distribution pattern of liposomes in tumors. Our findings demonstrate that high-resolution 3D visualization of nanomedicine distribution is a useful tool for preclinical nanomedicine research, providing valuable insights into the influence of the tumor vasculature and microenvironment on nanomedicine localization.
Chronic kidney disease, ejection fraction and heart failure in patients with occluded infarct-related arteries post-myocardial infarction: Data from the occluded artery trial
Authors: Vinod Jorapur, Jean Renkin, Zygmunt Sadowski, Harmony R. Reynolds, Antonio C. Carvalho, Christopher E. Buller, Jamie Rankin, P. G. Steg, Harvey White, Carlos Vozzi, Eduardo Balcells, Michael Ragosta, C. E. Martin, Jacqueline E. Tamis-Holland, Vankelpuran Srinivas, William Wharton, Staci J. Abramsky, Ana C. Mon, Bruce Barton, Gervasio A. Lamas, Judith S. Hochman
Journal: Circulation (2006)
The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.
Authors: Franck E Nicolini, Gabriel Etienne, Francoise Huguet, Agnès Guerci-Bresler, Aude Charbonnier, Martine Escoffre-Barbe, Viviane Dubruille, Hyacinthe Johnson-Ansah, Laurence Legros, Valerie Coiteux, Pascale Cony-Makhoul, Pascal Lenain, Lydia Roy, Philippe Rousselot, Denis Guyotat, Jean-Christophe Ianotto, Martine Gardembas, Eric Deconinck, Fabrice Larosa, Denis Caillot, Pascal Turlure, Stephane Courby, Philippe Quittet, Eric Hermet, Shanti Ame, Simona Lapusan, Alexandre Deloire, Stephane Morisset, Madeleine Etienne, Delphine Rea, Stephanie Dulucq, Francois-Xavier Mahon
Journal: Blood (2019)
Early T Cell Recovery of Thymus-Derived Naive T Cells and NK Cells in Pediatrics Patients after T-Cell Depleted HLA-Haploidentical Stem Cell Transplantation for Thalassemia.
Authors: Antonella Isgro’, Pietro Sodani, Marco Marziali, Buket Erer, Cecilia Alfieri, Javid Gaziev, Marco Andreani, Wilma Leti, Massimo Campagna, Fernando Aiuti, Guido Lucarelli
Journal: Blood (2007)
Assessment of Mortality and Its Associated Risk Factors in Patients with Transfusion Dependent Thalassemia in India
Authors: Rakesh Dhanya, Rajat Kumar Agarwal, Amit Sedai, Ankita Kumari, Lalith Parmar, Santhosh Hegde, Gayathri ., Ashwini Gowda, Pooja Gujjal, Pushpa H, J Dasaratha Ramaiah, Chandrakala Karri, Sujata Jali, Neelavva Tallur, U V Shenoy, Diana Pinto, Stalin Ramprakash, C P Raghuram, Deepa Trivedi, Xueyuan Cao, Lawrence Faulkner
Journal: Blood (2019)
Abstract 169: Association Between Time to First Administration of Epinephrine After Defibrillation and Outcome in Out-Of-Hospital Cardiac Arrest Patients With Shockable Rhythm
Authors: Shoji Kawakami, Yoshio Tahara, Teruo Noguchi, Satoshi Yasuda, Naohiro W Yonemoto, Hiroshi Nonogi, Ken Nagao, Takanori Ikeda, Naoki Sato, Hiroyuki Tsutsui
Journal: Circulation (2019)

Introduction: In out-of-hospital cardiac arrest (OHCA) patients during shockable rhythm, the epinephrine administration after second defibrillation is recommended by the 2015 ILCOR/CoSTR guidelines. However, there is insufficient evidence regarding the proper timing of epinephrine administration particularly in relation to defibrillation. Hypothesis: The timing of epinephrine after first defibrillation (D-E interval) was associated with clinical outcome in OHCA patients. Methods: Between 2011 and 2016, we enrolled 753,025 OHCA patients from nationwide prospective population-based registry in Japan. Following exclusion criteria, a total of 1,559 patients with witnessed by bystanders and shockable rhythm on the initial electrocardiogram who administrated epinephrine after defibrillation by emergency medical service personnel and obtained return of spontaneous circulation in prehospital setting were eligible for the study. We evaluated the association between D-E interval and favorable neurological outcome (cerebral performance category: 1 or 2) at 30 days. To evaluate predictor for better neurological outcome, study patients were categorized as every 2 minutes up to 20 minutes, and more than 20 minutes. Results: Patients with favorable neurological outcome were 22% (N=348). Patients with favorable neurological outcome had a shorter D-E interval than those with non-favorable neurological outcome (7.9±4.1vs 10.2±5.3 min, p&lt;0.001). Multivariate logistic regression analysis showed that D-E interval at more than 10 minutes, when D-E interval at 2 to 3 minutes as defined reference, was a significant predictor for non-favorable neurological outcome ( Table ). Conclusion: Delayed epinephrine administration after first defibrillation (D-E interval &gt;10 minutes) was significantly associated with non-favorable neurological outcome.
A Phase 1/2A Open-Label Study of Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lymphoproliferative Malignancies.
Authors: Steven M. Horwitz, Julie M. Vose, Ranjana Advani, Kamalesh Sankhala, Swaminathan Padmanabhan, Paul A. Hamlin, Andy Chen, Shannon Wilroy, Jasmine M. Zain, Danielle Wright, Hanna Weissbrot, Maribeth Hohenstein, Pablo J Cagnoni, Michael E Saunders, Owen A. O’Connor
Journal: Blood (2008)